AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2015
Jul 1, 2015
31801_dirs_2015-07-01_83d3bf12-7f3a-4c88-a36a-7235cb7eb8ba.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2015-07-01
Reporting Person: Wright Richard M. (Sr. VP & CCO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock, par value $0.001 per share | 3125 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $3.99 | 2022-06-01 | Common Stock (12500) | Direct | |
| Employee Stock Option (right to buy) | $16.36 | 2023-07-01 | Common Stock (20000) | Direct | |
| Employee Stock Option (right to buy) | $13.45 | 2024-06-04 | Common Stock (25000) | Direct | |
| Employee Stock Option (right to buy) | $25.41 | 2025-06-10 | Common Stock (75000) | Direct |
Footnotes
F1: The option became exercisable as to 25% of the shares on 6/1/2013. This option is currently vested as to 6,250 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 4 quarters.
F2: The option became exercisable as to 25% of the shares on 7/1/2014. This option is currently vested as to 10,000 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 8 quarters.
F3: The option became exercisable as to 25% of the shares on 6/4/2015. This option is currently vested as to 6,250 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F4: The option becomes exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.